News
IBRX
4.340
-2.91%
-0.130
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
 
Benzinga · 6d ago
BRIEF-Immunitybio Says FDA Accepts BLA For Bladder Cancer Carcinoma Treatment
BRIEF-Immunitybio Says FDA Accepts BLA For Bladder Cancer Carcinoma Treatment
Reuters · 07/28 22:09
FDA Accepts ImmunityBio's Bladder Cancer Candidate For Review
The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in sit...
Benzinga · 07/28 21:05
ImmunityBio Announces FDA Acceptance Of Biologics License Application For N-803 In BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. ((IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder
Benzinga · 07/28 20:54
FDA accepts ImmunityBio's biologics license application for bladder cancer treatment N-803
ImmunityBio (NASDAQ:IBRX) on Thursday <a href="https://seekinga...
Seekingalpha · 07/28 20:33
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
CULVER CITY, Calif., July 28, 2022--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive blad...
Business Wire · 07/28 20:18
Fauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated'
A new generation of vaccines is needed to continue fighting COVID-19, according to experts at the White House Tuesday.
Yahoo Finance · 07/26 20:17
ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex
The Los Angeles-based company is far different from Athenex, developing different kinds of cancer drugs and building its own business model around those plans, but it also has some notable similarities.
American City Business Journals · 06/30 14:00
TRIP, IBRX and BRZE among after hour movers
Gainers: Kezar Life Sciences (KZR) +99%. Iris Energy (IREN) +5%. Immunity (IBRX) +5%. Cognyte Software (CGNT) +4%. Braze (BRZE) +4%. Losers: Polestar Automotive Holding (PSNYW) -5%. TripAdvisor (TRIP) -4%. Robinhood Market (HOOD)
Seekingalpha · 06/27 21:27
Health authorities push for a vaccine patent waiver to 'genuinely' prepare for the next pandemic
The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.
Yahoo Finance · 06/14 15:25
ImmunityBio ASCO results show promise for therapies in bladder and pancreatic cancers
Data presented by ImmunityBio (NASDAQ:IBRX) at the American Society for Clinical Oncology Annual Conference showed positive results from two trials in bladder cancer carcinoma and advanced pancreatic cancer. In a
Seekingalpha · 06/06 14:39
ImmunityBio Announces QUILT Trial Results For BCG-Unresponsive Bladder Cancer And Advanced Metastatic Pancreatic Cancer At ASCO 2022
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting Data from trials underscore
Benzinga · 06/06 13:01
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
CULVER CITY, Calif., June 06, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a leading clinical-stage immunotherapy company, today announced new positive data from the company’s pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIB...
Business Wire · 06/06 13:00
--Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating
MT Newswires · 05/31 05:33
ImmunityBio files for FDA approval of N-803 BCG combo to treat bladder cancer
ImmunityBio (NASDAQ:IBRX) said it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of N-803 plus Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer
Seekingalpha · 05/23 13:19
BRIEF-ImmunityBio Submits BLA For N-803 Plus BCG For Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
reuters.com · 05/23 12:52
ImmunityBio Reports Submission Of Biologics License Application For N-803, Treatment Of Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer
Results for this FDA-designated Breakthrough Therapy exceed historical complete response rates and duration of response of current approved therapies for this indication CULVER CITY, Calif.--(BUSINESS WIRE)--
Benzinga · 05/23 12:38
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
CULVER CITY, Calif., May 23, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803, a first-in-class I...
Business Wire · 05/23 12:32
ImmunityBio Files Biologics License Application With FDA for Bladder Cancer Combination Immunotherapy
MT Newswires · 05/23 11:05
What Percentage Of ImmunityBio, Inc. (NASDAQ:IBRX) Shares Do Insiders Own?
A look at the shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) can tell us which group is most powerful. Insiders...
Simply Wall St. · 05/16 11:29
More
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about Immunitybio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its immunotherapy and cell therapy platforms include antibody cytokine fusion proteins; synthetic immunomodulators; vaccine technologies, which includes human adenovirus (hAd5) viral vector, and genetically modified off-the-shelf natural killer cells (NK cells), which activate both the innate (NK cell and macrophage) and adaptive (T cell) immune systems. Its lead cytokine fusion protein, Anktiva, is an interleukin-15 (IL-15) superagonist complex. Its clinical pipeline consists of approximately 26 actively recruiting clinical trials of which 17 are in Phase II or III development, across 13 indications in liquid and solid tumors, including bladder, pancreatic, and lung cancers, and infectious diseases, including SARS-CoV-2 and human immunodeficiency virus (HIV).